Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis

Annals of Otology, Rhinology and Laryngology

Volumn 112, Issue 9 I, 2003, Pages 780-786

  Sudhoff, Holger ^a,b   Faddis, Brian T ^a,c   Jung, Jae Y ^a,c   Hildmann, Henning ^a,b   Ebmeyer, Jörg ^a,b   Chole, Richard A ^a,c,d  

^a University of Bochum ^*

^b St Elisabeth Hospital Bochum   (Germany)

^c WASHINGTON UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Keratin; Osteoclastogenesis; Particle induced osteolysis; RANKL; Zoledronic acid

Indexed keywords

KERATIN; OSTEOPROTEGERIN; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; MINERAL;

APOPTOSIS; ARTICLE; BONE MARROW CELL; DOSE RESPONSE; DRUG MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NICK END LABELING; OSTEOLYSIS; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIVISION; DRUG EFFECT; MALE; METABOLISM; MOUSE; OSTEITIS; OSTEOCLAST; PATHOLOGY; PERIOSTEUM; PROSTHESES AND ORTHOSES; SKULL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BONE MARROW CELLS; BONE RESORPTION; CELL DIVISION; CELLS, CULTURED; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; INJECTIONS, SUBCUTANEOUS; KERATINS; MALE; MICE; MICE, INBRED C57BL; MINERALS; OSTEITIS; OSTEOCLASTS; OSTEOLYSIS; PARIETAL BONE; PERIOSTEUM; PROSTHESES AND IMPLANTS; SKULL;

EID: 0142120125     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940311200907     Document Type: Article

References (21)

1. Chole RA. The molecular biology of bone resorption due to chronic otitis media. Ann N Y Acad Sci 1997;830:95-109.
2. Greenfield EM, Bi Y, Miyauchi A. Regulation of osteoclast activity. Life Sci 1999;65:1087-102.
3. Roodman GD. Cell biology of the osteoclast. Exp Hematol 1999;27:1229-41.
4. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.
5. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-51.
6. Body JJ. Clinical research update: zoledronate. Cancer 1997;80(suppl):1699-701.
7. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999;14:1557-61.
8. Sudhoff H, Hildmann H, Michaels L. Cholesteatoma: pathogenesis. In: Ars B, ed. Pathogenesis in cholesteatoma. The Hague, the Netherlands: Kugler Publications, 1999:79-104.
9. Michaels L. Pathology of cholesteatoma: a review. J R Soc Med 1979;72:366-9.
10. Chole RA. Bone resorption in aural cholesteatoma. In: Nakano Y, ed. Proceedings of the Fourth International Conference on Cholesteatoma and Mastoid Surgery. The Hague, the Netherlands: Kugler Publications, 1994:79-84.
11. Hildmann H, Sudhoff H, Jahnke K. Grundzüge einer differenzierten Cholesteatomchirurgie. Laryngorhinootologie 2000;79(suppl 2):73-94.
12. McHugh KP, Hodivala-Dilke K, Zheng MH, et al. Mice lacking β3 integrins are otosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000;105:433-40.
13. Chole RA, Hughes RM, Faddis BT. Keratin particle-induced osteolysis: a mouse model of bone remodeling related to cholesteatoma. J Assoc Res Otolaryngol 2001;2:65-71.
14. Chole RA, Henry KR, McGinn MD. Cholesteatoma: spontaneous occurrence in the Mongolian gerbil Meriones ungiculatis. Am J Otol 1981;2:204-10.
15. Feinmesser R, Ungar H, Adler J. Otic cholesteatoma in the sand rat (Psammomys obesus). Am J Otol 1988;9:409-11.
16. Richardson AC, Tinling SP, Chole RA. Risedronate activity in the fetal and neonatal mouse. Otolaryngol Head Neck Surg 1993;109:623-33.
17. Buckler H, Fraser W, Hosking D, et al. Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study. Bone 1999;24(suppl):81S-85S.
18. Arden-Cordone M, Siris ES, Lyles KW, et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int 1997;60:415-8.
19. Muller K, Wiesenberg I, Jaeggi K, Green JR. Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat. Arzneimittelforschung 1998;48:81-6.
20. Pysklywec MW, Moran EL, Bogoch ER. Zoledronate (CGP 42'446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis. J Orthop Res 1997;15:858-61.
21. Coxon FP, Helfrich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000;15:1467-76.